![Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules](https://www.seventure.fr/wp-content/uploads/2016/11/4__104270789-1-322x211.jpg)
Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules
Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they...